Enhancing Patient Safety Saves Hospitals Millions: Learn How Much Yours Could Save

As COVID-19 and the unprecedented patient care challenges it brought to healthcare organizations recede, hospitals are still reeling from financial strains caused by the pandemic. The AHA estimates that hospitals will lose between $53 billion and $122 billion by the end of this year due to residual effects of COVID-19, depending on vaccine distribution and return of patient volumes.

Still, this is no time for hospitals to hit the brakes on patient safety improvements, even if stepping up patient safety initiatives may seem challenging in the face of significant financial losses. In fact, patient safety and a healthier bottom line go hand-in-hand; if you improve patient safety, your margins will also improve, and for hospitals to return to pre-pandemic patient volumes, it will be vital for hospitals to demonstrate that patient safety is a priority.

Calculating the Value

Healthcare consultancy Sage Growth Partners recently conducted an economic value assessment of the patient-safety enhancing features and functionalities of our clinical surveillance platform.

The assessment—which is based on metrics and reports from peer-reviewed studies, journals, government databases, and other sources—determines a hospital’s potential savings from implementing VigiLanz. The evaluation is customized based on factors such as annual inpatient admissions, number of staffed beds, and daily census.

The assessment found that most hospitals can save millions of dollars by implementing VigiLanz. For example, a small hospital with 50 staffed beds, 3,000 annual admissions, an average daily census of 30, and a bed utilization rate of 50 percent could experience $1.3 million in savings. A large hospital, with 900 staffed beds, 40,000 annual admissions, an average daily census of 700, and a bed utilization rate of 80 percent, could gain $15.5 million in savings.

Hospitals can input their own unique data in order to instantly receive a free, customized report. The report shows the total economic impact the hospital could experience, and it breaks that impact down by potential:

  1. Cost savings, due to faster and more proactive identification of opportunities to cut costs, such as IV to PO conversions and more optimal management of high-cost drugs.
  2. Cost avoidance, due to fewer costly events such as hospital acquired infections or conditions, acute kidney injuries due to antibiotic use, adverse drug events, readmissions, and return visits to the emergency department.
  3. Returned resources, the value of time saved by transitioning from manual to automated processes.

The tool also provides a breakdown of savings by area, such as pharmacy, infection prevention, and safety and quality.

To learn more and to get your custom savings report, please check out the tool. If you have any questions or are interested in learning more about how your hospital can use VigiLanz to improve patient safety and your bottom line, contact us today.

VigiLanz Ranked No. 1 by KLAS Research for Infection Control and Monitoring and Pharmacy Surveillance for Fourth Straight Year

The clinical surveillance company most trusted by hospitals is recognized as Best in KLAS, totaling 10 KLAS awards over 4 consecutive years

MINNEAPOLISFeb. 2, 2021 — VigiLanz, a clinical surveillance company, today announced that it has earned 2021 Best in KLAS designations from KLAS Research for Infection Control and Monitoring and Pharmacy Surveillance. This is the fourth year VigiLanz has been recognized by KLAS as a leader across both areas, and brings its total count of KLAS awards to 10. VigiLanz was also recognized in previous years in the Antimicrobial Stewardship category, which KLAS folded into Pharmacy Surveillance this year.

VigiLanz products earned Best in KLAS across two segments in the “2021 Best in KLAS: Software and Services” report, released on February 2:

Infection Control and Monitoring
Earning a score of 93.7, VigiLanz’s Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s EHR. Its exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“VigiLanz has been really good through the COVID-19 crisis because every time we need a new test, I just email the vendor, and they add it to the product. The vendor’s help has been a blessing.”

  • Physician, August 2020klasresearch.com  

Pharmacy Surveillance
Earning a score of 91.1, VigiLanz’s Dynamic PharmacoVigilance product acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for adverse drug event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“The product is extremely easy to use, and that has to be a big part of our success. Something that is hard to use or clunky wouldn’t work for our teams’ workflow. It doesn’t matter how good the quality of the material is; a clunky product wouldn’t work because we are moving at such a fast pace.

  • Manager, June 2020, klasresearch.com

In addition, VigiLanz’s Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, drug-bug mismatches, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and is certified by the National Healthcare Safety Network for easy, direct reporting on antibiotic use.

“I have found VigiLanz to be really helpful with their ability to fine-tune a rule and screen out a lot of noise. So we are getting exactly what we need. We can tease out geography, look at specific organisms, or look at different time frames. This is very powerful and very easy to do in the system.”

  • Director, January 2020, klasresearch.com

“In what’s proven to be a particularly challenging year for our hospital customers, we’re extremely proud to continue our recognition by KLAS four years in a row,” said VigiLanz Chairman and CEO David Goldsteen, MD. “We know our customers rely on us when they need it most—whether that’s triaging COVID-19 cases, monitoring the use of specific pharmaceuticals during a shortage, or saving clinicians time providing real-time alerts and reports so they can focus more on patients. It’s our job to help hospitals keep patients safe, and we’re honored to see the glowing feedback from this past year.”

Best in KLAS is a recognition given to vendors for outstanding efforts to help healthcare professionals deliver better patient care. The Best in KLAS designation is reserved for the software and services market segments that have the broadest operational and clinical impact on healthcare organizations. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.

Selected commentary collected about VigiLanz Infection Control and Monitoring and Pharmacy Surveillance, January 2021  © 2021 KLAS. Visit klasresearch.com for a complete view.

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

Media Contact
Boh Hatter
(410) 790.9570

Vigilanz Offers COVID-19 Vaccine Management Solution Free to Customers | Healthcare IT Today

VigiLanz, a clinical surveillance company, announced the launch of a new mass vaccination support software. The company is offering Vigilanz Vaccinate free to its existing customers to help frontline healthcare teams stay safe.

I had the chance to sit down with Stacy Pur, Vice President of Product Development at Vigilanz to find out more about their product and to talk through some of the unique challenges of these early vaccines.

Why Free?

“The COVID-19 issue is personal—at VigiLanz, we have had employees and family members contract COVID-19 and require medical intervention,” said David Goldsteen, VigiLanz’s CEO. “We are so grateful for the amazing care healthcare teams are delivering across the country, and we wanted to do something to help. It was important to us to offer this tool [Vigilanz Vaccinate] to current customers for free to help them and their frontline healthcare teams stay safe during this extremely challenging global pandemic. It’s the right thing to do.”

You can read more of this article on Healthcare IT Today.

Freeman Health System Uses VigiLanz to Enhance MRSA Screening, Reduce Vancomycin Use

Customer Profile

Freeman Health System, a 485-bed, three-hospital system in Joplin, Missouri, serves an area of 450,000 people across Missouri, Arkansas, Kansas, and Oklahoma. It is the #1 hospital in Southwest Missouri and the #4 hospital in Missouri, according to U.S. News & World Report.


Hospitals across the country are fighting to combat antibiotic overuse, resistance, and unwanted side effects, but many are struggling to implement new and effective workflows that help meet these goals. Much of the challenge boils down to speed and efficiency—hospitals need to identify antibiotic overuse more quickly, and intervene sooner when it does occur.

Freeman Health System is no exception to the challenges associated with antimicrobial stewardship (ASP), and it was looking for a way to improve its ASP processes, particularly related to vancomycin use among patients with pneumonia.

“Data shows that 98 percent of the time, a negative MRSA screen for a patient with pneumonia means that a patient does not have MRSA-pneumonia, and their empiric vancomycin therapy can safely be discontinued,” said Adrienne Carey, PharmD, BCPS, Clinical Pharmacist and Data Mining Program Manager at Freeman Health System. “We wanted to streamline our MRSA screening process so that we could more quickly identify if a MRSA screen is negative, and therefore, discontinue vancomycin use sooner.”


Freeman Health System’s antibiotic stewardship team had already changed the health system’s pneumonia pathway orders to ensure all patients who came into the ER automatically received a nasal screen for MRSA.

“Our pharmacy department was tasked with educating physicians about the change and with contacting them with the results,” said Carey. “The goal was to de-escalate patients’ antibiotics more quickly.”

The problem was that results were not always communicated quickly to pharmacists, so there was sometimes a delay in identifying patients whose vancomycin therapy could be discontinued.

Freeman Health System turned to VigiLanz to help, working with the VigiLanz clinical support team to create a negative MRSA screen rule within the system. Now, whenever a patient prescribed vancomycin has a negative MRSA screen and no other cultures are positive for MRSA, the pharmacy team and infectious disease physician receive an alert in real time.

“Before implementing the VigiLanz rule, we had to manually run reports through our health information system to view all patients on vancomycin, then check each patient’s microbiology results to see if they had been screened for MRSA,” said Carey. “That took a lot of time.”

Now, pharmacists and physicians can more quickly discontinue vancomycin use and switch to an alternate antibiotic when appropriate, she explained. “We are not leaving our patients on vancomycin any longer than necessary.”

Adrienne Carey, PharmD, BCPS describes real-time alerts helping pharmacists


In the first six months since November 2018, when the new workflow was implemented, Freeman Health System’s pharmacists worked with physicians to discontinue vancomycin therapy in 70 patients.

Other key benefits of the new approach include:

  • Time savings for pharmacists
  • Time savings for nurses by reducing doses and drawing fewer labs
  • Monetary savings by reducing unneeded antibiotics
  • Reduced risk of infection through an IV route since IV lines are discontinued sooner due to de-escalation
  • Fewer medication side effects
  • Less chance for antibiotic resistance
  • Improved patient satisfaction due to fewer medications being administered
  • Shorter lengths of stay

“Building this rule and receiving immediate alerts from VigiLanz is helping us better identify all patients who qualify to have their therapy de-escalated and do so in a timely fashion,” said Carey. “We have also seen a trend toward less vancomycin usage overall.”

Related Resource:

Economic Value Tool – Calculate Your Savings

Healthier Patients, Healthier Bottom Line

Calculate Your Savings
See how your hospital or health system could be using VigiLanz to save millions by optimizing efficiency and improving patient safety.

VigiLanz leads to savings throughout your health system—from the pharmacy department, to infection prevention, to overall quality and safety.

We’ve designed this calculator to provide insight into VigiLanz’s high economic impact. VigiLanz improves workflow and staffing efficiency, reduces and prevents costly safety errors and adverse events, and identifies cost-savings opportunities such as IV to PO conversions.

The tool starts with national benchmark data, but allows you to enter your own organization’s information for a more customized analysis. See your hospital’s potential savings in key areas, plus, receive a full report to see hospital-wide savings and a detailed description of the key savings drivers and methodology.

VigiLanz Improves Efficiency, Patient Care at Riverside University Health System

Andy Williams, PharmD, BCPP, BCGP, Senior Clinical Pharmacist at Riverside University Health System, discusses how VigiLanz improves patient care.

“I’ve seen VigiLanz make some very strong, important interventions, especially in the realm of our pharmacokinetic monitoring,” says Williams, adding that VigiLanz serves as a second set of eyes for pharmacists.

Watch this short video to learn more about how Williams and his team are using VigiLanz to improve patient care.



I think the biggest benefit that VigiLanz provides for patient care is that it helps us work more efficiently, so we’re able to quickly get the information that we need, so that we can spend more time out on treatment team rounds or out directly interacting with patients on the unit  conducting our pharmacist-led patient education groups. It helps us to take care of any reports or lab monitoring we need to do quickly and efficiently, so that we’re able to then realign our time on something else that could help strengthen patient care.

Since we are a psychiatric hospital, we may have a little bit unique methods in which we use VigiLanz. We use VigiLanz largely for our reports, so it’s able to help us with conducting our quality assurance measures. We’re able to run reports on which patients have received long-acting injectable anti-psychotics each quarter, and then cross compare that with their readmission rates. We’re able to use it to run our Joint Commission Hospital-Based Inpatient Psychiatric Services measures to see patients that are on two or more anti-psychotics. We’re able to use it to run whether or not they have appropriate labs, so if they have their lipid panels or their A1Cs for the patients that are receiving second generation antipsychotics, as well as for pharmacokinetic monitoring of Lithium or valproic acid sodium. 

I’ve seen VigiLanz make some very strong, important interventions, especially in the realm of our pharmacokinetic monitoring. Many of our patients are receiving Lithium, which is a narrow therapeutic index drug, and with that, it has the potential for many drug interactions. It could be very easy for one of our pharmacists to overlook a lab or not see an out-of-range lab. VigiLanz is able to provide that safety net and that second look of eyes to alert us in real time if something is out of range so that we can act quickly, without leaving the patient exposed to a higher level or risk them receiving another dose when that really isn’t appropriate.”

VigiLanz Provides Efficiency Improvements, Life-Saving Interventions at Freeman Health System

Adrienne Carey, PharmD, BCPS, Clinical Pharmacist at Freeman Health System, discusses how VigiLanz improves efficiency and helps saves patients’ lives.

“VigiLanz impacts our efficiency because it shows us what we need to intervene on in real time,” says Carey. “We use our health information system also, but we are pretty much living in the VigiLanz system because it’s real time.”

Watch this short video to learn more about how Carey and her team are using VigiLanz to improve patient care.


VigiLanz impacts our efficiency because it shows us what we need to intervene on in real time. So we use, especially our clinical pharmacists on the floor, we live in the VigiLanz software. We use our health information system also, but we are pretty much living in the VigiLanz system because it’s real time. We use it for our medication reconciliation program, so our technicians use it to document all the information that they gather when compiling the patient’s home medication list. We also use it for our clinical pharmacists and our staff pharmacists throughout our system to document all of our activities to help us identify patients that might need some type of intervention from a pharmacist, whether it’s dosing or looking at their IV status or whether we can switch their medications from IV to PO. We look at their antibiotic usage to make sure that we’re covering their bugs appropriately.

We have seen VigiLanz help us identify life-saving interventions for our pharmacy department. For example, we have a rule to help us identify those that are on anticoagulants that have been discontinued or put on hold. So typically when you are on anticoagulants, that’s not something that’s put on hold and then stopped indefinitely; that’s usually something that’s temporarily put on hold and then we really need to resume it after your procedure or after whatever surgery we’re doing or test we’re doing is done. So it has helped us identify those people who it’s been put on hold but somehow it got missed putting back on. Without the anticoagulation, we run the risk of heart attacks, and strokes, and things like that, so the rules that help us find those patients who were on it but for some reason are no longer on it have been very important.

My favorite part of working with VigiLanz has honestly been the customer support. So we have a person on the VigiLanz side on the customer support team that I can submit a ticket to at any moment and they are experts and they are wonderful at getting back to me very quickly and helping me work through whatever issue it is. I’m kind of a do-it-yourself person, so I usually try to create the rules or fix things that I want for our system, but sometimes I come to a roadblock and I usually submit a ticket and the pharmacist on their end has been absolutely wonderful to work with. That’s not something I’ve ever had with any software program I’ve used before.

VigiLanz Helps Pharmacists ‘Work Smarter, Not Harder’ at Antelope Valley Hospital

Jill Bennett, PharmD, BCPS, Clinical Coordinator/Residency Program Director at Antelope Valley Hospital, discusses how VigiLanz has transformed work flows, and is helping staff members work smarter, not harder.

“Certainly the information that you put in more than represents what you can get out of it and the benefit it can add,” she says. “You can get to so much more than you can utilizing manual reporting.”

Watch this short video to learn more about how Bennett and her team are using VigiLanz to improve patient care.

Transcribed video:

On a day to day basis, VigiLanz really drives our work. It’s changed the way we work. We work smarter, not harder, and we’ve been able to really increase what we’re looking at. So, initially what we had to do manually by generating reports and looking at things like certain medications that were given intravenously that could be changed to oral therapy, we instead were able to have it filter through and look at whether or not the patient was on other oral medications, maybe was eating, those types of things that would let us get in tune to the changes that we could make more quickly.

It really drives our work flow. We have the alerts, that’s part of it. Another piece, is certainly our antimicrobial stewardship work. We utilize the antimicrobial stewardship list, and it’s really nice to be able to focus in on which patients need to be seen that are stewardship patients and then actually to be able to check them off and note when we’ve done the follow-up or when we’ve made the needed interventions. So things like drug-bug mismatches, being able to de-escalate therapy when we have those final culture results in, things like that.

I’ve been a real proponent of VigiLanz. I mean I always feel very comfortable in recommending it to other healthcare systems and I feel really lucky that we have this available to us because there certainly are a lot of people that want it and have not been able to justify it in the right way maybe to their administration.

Certainly the information that you put in more than represents what you can get out of it and the benefit it can add. You can get to so much more than you can utilizing manual reporting. So you do work smarter, you can get too many more things, and therefore you use your resources more wisely. It’s been really beneficial to us.

VigiLanz Announces Precision Dosing Powered by Tabula Rasa HealthCare’s DoseMeRx

 DoseMeRx to integrate with VigiLanz clinical surveillance solutions for hospitals

MOORESTOWN, N.J., (April 02, 2020) – Tabula Rasa HealthCare, Inc® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, has partnered with VigiLanz®, the leading provider in clinical surveillance, to integrate with DoseMeRx™, TRHC’s precision dosing solution. The integration of DoseMeRx within VigiLanz’s award winning software platform will provide hospital customers with instant access to personalized dosing for vancomycin and other antimicrobials, optimizing pharmacy workflow and improving patient safety.

Learn more

VigiLanz is the 2020 Category Leader for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance by KLAS Research. This is the third consecutive year, VigiLanz ranked top for Pharmacy Surveillance and second year in a row ranking top for Antimicrobial Stewardship and Infection Control and Monitoring.

“Our partnership with Tabula Rasa HealthCare and DoseMeRx enables providers to easily optimize the dosing of vancomycin and other high-risk antimicrobials,” said VigiLanz Chairman and CEO David Goldsteen, MD. “This is especially critical with the release of the new vancomycin dosing guidelines, which are indicative of a growing trend toward increased medication safety. DoseMeRx brings immense value to pharmacists. Together, we’re excited to bring precision dosing to our customers.”

The VigiLanz platform provides leading pharmacy surveillance and antimicrobial stewardship solutions for hospitals to generate real-time alerts that help clinicians make appropriate drug therapy decisions. Adding DoseMeRx will enable VigiLanz customers to easily implement the new national dosing guidelines for vancomycin – one of the most commonly used antibiotics in hospitals today.

“This partnership means convenient access for VigiLanz customers to the precision dosing capabilities of DoseMeRx to optimize the use of vancomycin in the acute care setting,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Our goal is to expand and scale the use of DoseMeRx, along with other TRHC platforms, to more pharmacists who will use it to optimize medication safety.  This partnership does just that.

According to TRHC Executive Vice President for DoseMe/Hospitals Business Unit  Charles Cornish, the opportunity to integrate DoseMeRx with the VigiLanz solution is of benefit to customers looking for a closed-loop solution to clinical surveillance and dose optimization. “VigiLanz and TRHC share the common goal of building easy-to-use clinical decision software with the ability to improve workflows and support pharmacists,” said Cornish.


About Tabula Rasa HealthCare
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com.


About DoseMeRx

DoseMeRx is a Tabula Rasa HealthCare (NASDAQ: TRHC) solution. It is the first precision dosing software developed specifically for clinical practice. The DoseMeRx clinical decision support platform empowers healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs and improve patient outcomes. For more information on DoseMeRx, visit doseme-rx.com


About VigiLanz

Founded in 2001, VigiLanz is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. To learn more about VigiLanz Precision Dosing, powered by DoseMeRx, visit info.vigilanzcorp.com/precision-dosing.


Forward-Looking Statements
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology.  Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions.  These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release.  Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC,  including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

A Message from David Goldsteen, MD, VigiLanz CEO

To our hospital partners and healthcare providers,

Thank you for the long hours you are working, the risks you are taking, and the sacrifices you are making to care for patients with COVID-19. VigiLanz is here to support you in any way that we can.

Over the past few weeks, you’ve shared some of your top challenges with us. We’ve also gathered insights from our internal clinical team. Based on these discussions, we’re enabling new COVID-19 related rules, reports, and alerts almost daily and supporting custom requests based on the unique needs of each hospital.

We’ve also created a new COVID-19 Testing Results report. This report compiles all patients with a COVID-19 order, positive/negative lab result, or positive microbiology report. In addition, it includes patient demographics, clinical parameters like temperature, SpO2, FiO2, medications, and discharge disposition. As with all of our reports, it can be exported to Excel after it’s generated.

As the COVID-19 crisis evolves and your needs change, we will continue to reach out and identify new ways to help. We’ll share that information here, on our website, and in emails.

In the meantime, please let us know if there are any other ways we can support you.

With gratitude for the important work you’re doing.


David Goldsteen, MD, MBA
Chairman & CEO, VigiLanz